What is the recommended dose of Bismuth subcitrate for an adult patient with Helicobacter pylori infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bismuth Subcitrate Dosing for Helicobacter pylori Infection

For adult patients with H. pylori infection, bismuth subcitrate should be dosed at 120-140 mg four times daily (or 240 mg twice daily) as part of bismuth quadruple therapy for 14 days. 1, 2

Standard Dosing Regimen

The complete bismuth quadruple therapy regimen consists of: 3, 1, 2

  • Bismuth subcitrate: 120 mg four times daily (or 240 mg twice daily depending on formulation) 2, 4
  • Tetracycline: 500 mg four times daily 3, 2
  • Metronidazole: 500 mg three to four times daily 3, 2
  • PPI: Standard dose twice daily (e.g., omeprazole 20 mg, esomeprazole 20 mg, pantoprazole 40 mg) 3, 2

Treatment duration must be 14 days to maximize eradication rates of 80-90%, as shorter durations of 7-10 days achieve only 80-82% eradication. 3, 1, 5

Dosing Equivalents and Formulations

Different bismuth formulations exist, but the key is achieving approximately 300 mg of elemental bismuth four times daily: 3, 1

  • Bismuth subcitrate: 120-140 mg four times daily or 240 mg twice daily 2, 4
  • Bismuth subsalicylate: 262 mg (2 tablets) four times daily 1, 5
  • Bismuth potassium citrate: 220 mg twice daily (elemental bismuth) 6, 7

The total daily bismuth dose of approximately 1200 mg is critical for achieving optimal eradication rates and cannot be reduced without compromising efficacy. 5

Evidence Supporting This Dosing

Research demonstrates that bismuth-based quadruple therapy achieves 93-99% per-protocol eradication rates even in patients with metronidazole resistance (which affects 45-96% of strains), because bismuth's synergistic effect overcomes in vitro resistance. 8, 6, 7 A study using bismuth subcitrate 240 mg twice daily with tetracycline and metronidazole achieved 95% intention-to-treat cure rates. 8

Importantly, bismuth absorption is not required for efficacy—poorly absorbed bismuth preparations work equally well, making bismuth subcitrate (which has lower systemic absorption) preferable from a safety standpoint. 9

Critical Optimization Factors

Beyond bismuth dosing, these factors are mandatory for success: 1, 5

  • High-dose PPI twice daily (not once daily) increases efficacy by 6-10%, with esomeprazole or rabeprazole 40 mg twice daily providing an additional 8-12% benefit 1, 5
  • Take PPI 30 minutes before meals on an empty stomach without concomitant antacids 3, 1
  • 14-day duration is mandatory—extending from 7 to 14 days improves eradication by approximately 5% 3, 1, 5

Pediatric Dosing Considerations

For children, bismuth subcitrate dosing differs by age: 4

  • Under 12 years: 120 mg twice daily 4
  • Over 12 years: 240 mg twice daily 4

However, tetracycline is contraindicated in children under 8 years due to tooth discoloration risk, so alternative regimens should be used in this age group. 4

Common Pitfalls to Avoid

Do not reduce the bismuth dose below the recommended 120 mg four times daily (or 240 mg twice daily)—a reduction to 232 mg three times daily represents a 42% dose reduction that is not supported by any guideline and will compromise eradication rates. 5 The standard dosing achieving ~300 mg four times daily is critical for the 80-90% eradication rates reported in guidelines. 1, 5

Do not substitute doxycycline for tetracycline, as this produces inferior results. 2 Tetracycline 500 mg four times daily is the specific formulation required. 3, 2

References

Guideline

Helicobacter Pylori Infection Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Bismuth Quadruple Therapy for H. pylori Eradication

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

H. pylori Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.